NCT00092859已完成3 期
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of MK0557 in Obese Patients
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,500
- 主要终点
- Body weight after 1 year of treatment. Safety and tolerability for 2 years.
研究概览
简要总结
This is a 2-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Obese men and nonpregnant women at least 18 years of age with a specific body mass index (height and weight ratio) required by the study
排除标准
- •Patients with uncontrolled high blood pressure and/or diabetes mellitus (high blood sugar)
结局指标
主要结局
Body weight after 1 year of treatment. Safety and tolerability for 2 years.
时间窗: After 1 & 2 years of treatment
次要结局
- Durability of weight loss over two years.(Over two years.)
研究者
相似试验
已完成
1 期
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly ParticipantsHealthyNCT01887535Janssen Research & Development, LLC70
进行中（未招募）
1 期
Study designed to evaluate the safety and efficacy of Evolocumab compared with placebo, in people with diabetes who have high cholesterol and who are already taking statin treatmentHyperlipidemia or mixed dyslipidemia in Diabetic SubjectsEUCTR2013-000723-14-FRAmgen Inc.900
已完成
3 期
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fractioinsufficient pump function of the heart10019280Heart failureNL-OMON50612Amgen180
已完成
3 期
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia (study 20110117)10027424elevated cholesterolhypercholesterolemiaNL-OMON39059Amgen BV80
已完成
3 期
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Diseaseelevated cholesterol1008220610000546dyslipidemiaNL-OMON53167Amgen998